Study of stroke therapy highlights the potential value of preclinical trials in solving the ‘reproducibility crisis’ in clinical trials

Written by Alice Weatherston

In an effort to bridge the gap between the lab and the clinical setting, the European Consortium has put a potential new stroke therapy to the test in an animal study matching the requirements of a human clinical trial. The results, which were published recently in Science Translational Medicine, indicate that preclinical randomized controlled trials (pRCT) could aid in choosing the most promising drug candidates from lab-based studies before commencing potentially ineffective and costly clinical trials. The European Consortium sought to investigate the efficacy of the candidate stroke drug termed CD49d-specific antibody therapy (natalizumab), which is currently in a Phase...

To view the full article, please register now for access

It's completely free